Cargando…

Exposure to vitamin k antagonists and kidney function decline in patients with atrial fibrillation and chronic kidney disease

BACKGROUND: Exposure to vitamin K antagonists (VKA) has been suggested to accelerate progression of chronic kidney disease (CKD) but robust clinical data are currently lacking. METHODS: We retrospectively evaluated the impact of VKA exposure on kidney function in patients with atrial fibrillation (A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Posch, Florian, Ay, Cihan, Stöger, Herbert, Kreutz, Reinhold, Beyer‐Westendorf, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles: Thrombosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462762/ https://www.ncbi.nlm.nih.gov/pubmed/31011705 http://dx.doi.org/10.1002/rth2.12189

Ejemplares similares

Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D‐Dimer analysis: A prospective study
por: Posch, Florian, et al.
Publicado: (2020)

Perioperative interruption of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: A comparative analysis
por: Shaw, Joseph R., et al.
Publicado: (2020)

Extended anticoagulation treatment for cancer‐associated thrombosis—Rates of recurrence and bleeding beyond 6 months: A systematic review
por: Moik, Florian, et al.
Publicado: (2021)

INR and vitamin K–dependent factor levels after vitamin K antagonist reversal with 4F-PCC or plasma
por: Hood, Christopher, et al.
Publicado: (2022)

Direct oral anticoagulants compared to low‐molecular‐weight heparin for the treatment of cancer‐associated thrombosis: Updated systematic review and meta‐analysis of randomized controlled trials
por: Moik, Florian, et al.
Publicado: (2020)

Lupus anticoagulant test persistence over time and its associations with future thrombotic events
por: Colling, Meaghan E., et al.
Publicado: (2022)

Impact of different anticoagulation management strategies on outcomes in atrial fibrillation: Dutch and Belgian results from the GARFIELD‐AF registry
por: Seelig, Jaap, et al.
Publicado: (2020)

The Importance of Appropriate Dosing of Nonvitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation
por: Beyer-Westendorf, Jan, et al.
Publicado: (2021)

Pulmonary embolism during the COVID‐19 pandemic: Decline in diagnostic procedures and incidence at a university hospital
por: Nopp, Stephan, et al.
Publicado: (2020)

Association of complete blood count parameters, d‐dimer, and soluble P‐selectin with risk of arterial thromboembolism in patients with cancer
por: Grilz, Ella, et al.
Publicado: (2019)

Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer
por: Grilz, Ella, et al.
Publicado: (2019)

Non-vitamin K antagonist oral anticoagulants vs. vitamin-K antagonists in patients with atrial fibrillation and chronic kidney disease: a nationwide cohort study
por: Laugesen, Emma Kirstine, et al.
Publicado: (2019)

Clinical outcome of patients with a vitamin K antagonist‐associated bleeding treated with prothrombin complex concentrate
por: Brekelmans, Marjolein P. A., et al.
Publicado: (2017)

Efficacy and Safety of Vitamin K-Antagonists (VKA) for Atrial Fibrillation in Non-Dialysis Dependent Chronic Kidney Disease
por: Kooiman, Judith, et al.
Publicado: (2014)

Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with advanced chronic kidney and liver diseases
por: Liao, Jo-Nan, et al.
Publicado: (2022)

Effect of anticoagulants on fibrin clot structure: A comparison between vitamin K antagonists and factor Xa inhibitors
por: Gauer, Julia S., et al.
Publicado: (2020)

Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis
por: Nopp, Stephan, et al.
Publicado: (2020)

Development of a clinical prediction model for an international normalised ratio ≥ 4·5 in hospitalised patients using vitamin K antagonists
por: Dreijer, Albert R., et al.
Publicado: (2018)

Self‐reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
por: Peeters, Frederique E. C. M., et al.
Publicado: (2018)

Global public awareness about atrial fibrillation
por: Wendelboe, Aaron M., et al.
Publicado: (2017)

Awareness of venous thromboembolism among patients with cancer: Preliminary findings from a global initiative for World Thrombosis Day
por: Potere, Nicola, et al.
Publicado: (2022)

Quality of life and functional limitations after pulmonary embolism and its prognostic relevance
por: Keller, Karsten, et al.
Publicado: (2019)

Detection of upper extremity deep vein thrombosis by magnetic resonance non‐contrast thrombus imaging
por: van Dam, Lisette F., et al.
Publicado: (2021)

Effects of direct oral anticoagulants vs. vitamin K antagonists on acute kidney injury in patients with atrial fibrillation: A systematic review
por: Ren, Chengfa, et al.
Publicado: (2023)

Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors
por: Schweiger, Helmut, et al.
Publicado: (2022)

Atrial fibrillation and cancer: prevalence and relative risk from a nationwide study
por: Ay, Cihan, et al.
Publicado: (2022)

Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation
por: Botto, Giovanni Luca, et al.
Publicado: (2021)

Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study
por: Zielinski, Gilda Denise, et al.
Publicado: (2019)

Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation
por: Undas, Anetta, et al.
Publicado: (2020)

Atrial fibrillation, venous thromboembolism, ischemic stroke, and all‐cause mortality: The Tromsø study
por: Hald, Erin Mathiesen, et al.
Publicado: (2020)

Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in management of major bleeding
por: Abdoellakhan, Rahat A., et al.
Publicado: (2019)

Novel inhibitor ZED3197 as potential drug candidate in anticoagulation targeting coagulation FXIIIa (F13a)
por: Pasternack, Ralf, et al.
Publicado: (2019)

Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends
por: Shiyovich, Arthur, et al.
Publicado: (2021)

Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation
por: Giugliano, Robert P
Publicado: (2022)

Use of non-vitamin K antagonists oral anticoagulants in atrial fibrillation patients on dialysis
por: Li, Wenhao, et al.
Publicado: (2022)

Low-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
por: Lee, Ki Hong, et al.
Publicado: (2023)

Perioperative interruption of direct oral anticoagulants in patients with atrial fibrillation: A systematic review and meta‐analysis
por: Shaw, Joseph R., et al.
Publicado: (2018)

Relation of the ‘Atrial Fibrillation Better Care (ABC) Pathway’ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists
por: Roldán, Vanessa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r7m5jot7kba0it42iijq871bnm